Skip to main content

IRE1 INHIBITOR IV KIRA6 1PC X 10MG (C005B-229422)

Catalog No.
C005B-229422
Mfr. No.
5322810001
Mfr. Name
Sigma-Aldrich
Qty/UOM
10
UOM
MG
Price: $496.33
List Price: $551.48

A cell-permeable imidazopyrazinyl-naphthalenyl-phenylurea compound that acts as an IRE1α-selective type II kinase inhibitor (IC 50 = 0.6 µM IC 50 >10 µM against Erk2, JNK2, JNK3, Pak4, Pim1, PKA) by targeting ATP-binding site in

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account. Contact Us

Adding to cart… The item has been added

General description

A cell-permeable imidazopyrazinyl-naphthalenyl-phenylurea compound that acts as an IRE1α-selective type II kinase inhibitor (IC50 = 0.6 µM; IC50 >10 µM against Erk2, JNK2, JNK3, Pak4, Pim1, PKA) by targeting ATP-binding site in its inactive conformation. Stabilizing IRE1α kinase domain in an inactive conformation by KIRA6 prevents IRE1α oligomerization and subsequent RNase domain activity induction, resulting in effective inhibition against stress-induced cellular IRE1α oligomerization (5 mM DTT for 6 h +/1 µM KIRA6) & phosphorylation (1 h 10 µM; KIRA6 pretretament prior to 1 µM Tg/586005 & 586006 for 2 h), XBP1 mRNA splicing (IC50 = 2 µM; 1 h KIRA6 pretreatment prior to 0.5 µg/mL Tm/654380 & 504570 for 8 h), Ins1 mRNA degradation (IC50 = 0.5 µM; 1 hKIRA6 pretretament prior to 0.5 µg/mL Tm for 12 h), and apoptosis (% annexin V + cells = 22% vs. 60% post 72 h 0.25 µg/mL BFA/203729 & 500583 treatment with or without 0.5 µM KIRA6; No BFA control = 16%) in rat insulinoma INS-1 cultures without significant cytotoxicity (up to 10 µM for 72 h). Blockage of stress-induced apoptosis is similarly observed in primary human & murine islets cultures (0.5 µg/mL Tm for 16 h +/ 0.5 µM KIRA6) with a concomitant recovery of glucose-stimulated insulin secretion. KIRA6 is bioavailable via intraperitoneal injection in mice (Plasma Cmax/t1/2/AUC0-24 h = 3.3 µM/3.90 h/14.3 µM·h; 10 mg/kg BALB/c i.p.) in vivo with no apparent animal toxicity and is efficacious (5 or 10 mg/kg/12 h for 33 to 37 days) in reducing high blood glucose level due to chronic ER stress-induced β cell loss among Ins2+/Akita mice expressing proinsulin C96Y mutant with oxidative folding defect. Likewise, KIRA6 co-administration is shown to significantly reduce Rhodopsin mRNA degradation 96 h post Tm intraveal injection (2 µL per eye, final vitreal [Tm] & [KIRA6] = 20 µg/µL & 10 µM, respectively) in a rat model of acute photoreceptor loss in vivo, despite a rapid vitreal clearance (t1/2<60 h). Synergistic cytoprotection is demonstrated when combined with STF-083010 (Cat. No. 412510) that covalently modifies IRE1 RNase domain Lys907 in Tm-treated INS-1 cultures.

A cell-permeable, bioavailable, non-toxic, imidazopyrazinyl-naphthalenyl-phenylurea based compound that acts as a potent, ATP-competitive, reversible, and selective inhibitor of IRE1α kinase (IC50 = 600 nM). Exhibits good selectivity over ERK2, JNK2, JNK3, PIM1, PAK4, and PKA (IC50 >10 µM). Stabilizes the kinase domain of IRE1α in an inactive conformation and blocks its oligomerization and thereby reduces RNase domain activity. Shown to block brefeldin A-(Cat. Nos. 203729 & 500583) induced ER stress and apoptosis in INS-1 cells and tunicamycin (Cat. Nos. 654380 & 504570)-induced apoptosis in β-cells derived from C57BL/6 mice. Affords significant cytoprotection in combination with STF-083010 (Cat. No. 412510, 1 µM) and KIRA6 (50 nM). Systemic administration of KIRA6 in the Akita diabetic mice is shown to reduce their blood glucose levels, improve glucose tolerance, and conserve their β-cell function. Preserves photoreceptor function in a transgenic rat model (P23H) of chronic ER stress-induced retinal degeneration, when administered intravitreally. Displays desirable pharmacokinetic properties with t1/2 = 3.9 h and moderate clearance rate of 22.4 ml/min/kg in BABL/c mice (10 mg/kg, i.p.).

Please note that the molecular weight for this compound is batch-specific due to variable water content.

Biochem/physiol Actions

Cell permeable: yes

Primary Target
IRE1α kinase

Reversible: yes

Packaging

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)

Reconstitution

Use only fresh DMSO for reconstitution.

Other Notes

Ghosh, R., et al. 2014. Cell.158, 534.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Molecular Weight: 518.53. Empirical Formula: C28H25F3N6O. Assay: ≥. 95% (HPLC). Quality Level: 100. form: powder. manufacturer/tradename: Calbiochem®. . storage condition: OK to freeze, protect from light. color: off-white to brown. solubility: DMSO: 50 . mg/mL. storage temp.: 2-8°C. Storage Class Code: 11 - Combustible Solids. WGK: WGK 3. Flash Point(F): Not applicable. Flash Point(C): Not applicable.
UPC:
12352200
Condition:
New
Availability:
3-5 Days
Weight:
1.00 Ounces
HazmatClass:
No
MPN:
5322810001

Cenmed Satisfaction Guarantee
Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.

Testimonial
"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR

Testimonial
"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER

Testimonial
"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN

Testimonial
"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.